
Repligen (RGEN) Stock Forecast & Price Target
Repligen (RGEN) Analyst Ratings
Bulls say
Repligen demonstrated significant growth in its revenue streams, with CDMO and biopharmaceutical revenues increasing over 20% year-over-year, while consumables and capital equipment revenues also saw similar growth. The company raised its full-year 2025 revenue guidance to a range of $715-735 million, up from a previous estimate of $695-720 million, reflecting an optimistic outlook for future performance. Notably, Repligen also reported double-digit revenue and order volume increases across all product categories, indicating robust demand and a strong position within the bioprocessing market.
Bears say
Repligen has lowered its forecast for 2025 adjusted operating margin and adjusted EBITDA margin, indicating potential challenges in maintaining profitability. The company faces risks associated with product technology reliability and customer orders, which could lead to lost revenue, delayed market acceptance, and increased costs, ultimately impacting its financial performance. Additionally, despite a solid performance in certain areas, any decline in large customer orders poses a significant threat to Repligen’s revenues and overall financial condition.
This aggregate rating is based on analysts' research of Repligen and is not a guaranteed prediction by Public.com or investment advice.
Repligen (RGEN) Analyst Forecast & Price Prediction
Start investing in Repligen (RGEN)
Order type
Buy in
Order amount
Est. shares
0 shares